Stage 0 Breast Cancer
17
2
4
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
12%
2 trials in Phase 3/4
64%
7 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (17)
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
The PREDICT Registry:
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
A Study of Revaree Plus in People With Breast Cancer
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
eHealth Weight Loss Program in African American Breast Cancer Survivors
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer